文献速递特殊人群用药治疗药物监测与药物基因组学

基于年龄、性别、族裔、体重和吸烟状态的氯氮平群体药代动力学剂量选择模型

A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status.
PubMed 文献 · Br J Clin Pharmacol · 2023-03-02

本研究利用1993至2017年治疗药物监测服务数据,建立群体药代动力学模型分析氯氮平及去甲氯氮平的血浆浓度。结果显示氯氮平清除率随年龄增长而下降,并据此预测达到谷浓度0.35 mg L-1所需的剂量,该剂量受吸烟、性别、族裔和年龄显著影响。

要点

  • 氯氮平血浆清除率在20至80岁间从20.2降至12.0 L h-1。
  • 40岁不吸烟白人男性70 kg预测剂量为275 mg day-1(90%预测区间125, 625)。
  • 吸烟者预测剂量增加30%,女性降低18%,非裔加勒比裔高10%,亚裔低14%。

核心结论

  • 大样本和宽年龄范围使模型能精确估计达到谷浓度0.35 mg L-1的剂量需求。
  • 分析缺乏临床结局数据,需未来研究确定65岁以上人群的最佳谷浓度。

研究设计与样本

  • 基于1993-2017年氯氮平治疗药物监测服务数据的群体药代动力学分析,使用Monolix建模。

主要发现

  • 氯氮平血浆清除率在20至80岁间从20.2降至12.0 L h-1。
  • 40岁不吸烟白人男性70 kg达到谷浓度0.35 mg L-1的预测剂量为275 mg day-1(90%预测区间125, 625)。
  • 吸烟者预测剂量增加30%,女性降低18%,非裔加勒比裔高10%,亚裔低14%。
  • 预测剂量在20至80岁间总体下降56%。

关键数值与推荐

  • 目标谷浓度(predose plasma clozapine concentration)为0.35 mg L-1。
  • 参考患者:不吸烟、白人男性、体重70 kg、年龄40岁,预测剂量275 mg day-1(90%预测区间125, 625)。
  • 吸烟者剂量增加30%,女性降低18%,非裔加勒比裔高10%,亚裔低14%。
  • 20至80岁间预测剂量下降56%。

临床怎么用

  • 临床可根据年龄、性别、族裔、体重和吸烟状态调整氯氮平剂量以达目标谷浓度。
  • 老年患者需注意清除率下降,剂量应相应降低。
  • 吸烟状态和族裔是剂量选择的重要考量因素。

局限性

  • 缺乏临床结局数据。
  • 需未来研究确定65岁以上人群的最佳谷浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Guidance on clozapine dosing in treatment-resistant schizophrenia is based largely on data from White young adult males. This study aimed to investigate the pharmacokinetic profiles of clozapine and N-desmethylclozapine (norclozapine) across the age range, accounting for sex, ethnicity, smoking status and body weight. METHODS: A population pharmacokinetic model, implemented in Monolix, that linked plasma clozapine and norclozapine via a metabolic rate constant, was used to analyse data from a clozapine therapeutic drug monitoring service, 1993-2017. RESULTS: There were 17 787 measurements from 5960 patients (4315 male) aged 18-86 years. The estimated clozapine plasma clearance was reduced from 20.2 to 12.0 L h-1 between 20 and 80 years. Model-based dose predictions to attain a predose plasma clozapine concentration of 0.35 mg L-1 was 275 (90% prediction interval 125, 625) mg day-1 in nonsmoking, White males weighing 70 kg and aged 40 years. The corresponding predicted dose was increased by 30% in smokers, decreased by 18% in females, and was 10% higher and 14% lower in otherwise analogous Afro-Caribbean and Asian patients, respectively. Overall, the predicted dose decreased by 56% between 20 and 80 years. CONCLUSION: The large sample size and wide age range of the patients studied allowed precise estimation of dose requirements to attain predose clozapine concentration of 0.35 mg L-1 . The analysis was, however, limited by the absence of data on clinical outcome and future studies are required to determine optimal predose concentrations specifically in those aged over 65 years.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Reeves S, Bertrand J, Obee SJ, et al. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol. 2023. PMID: 36793249. doi:10.1111/bcp.15691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。